I told you, they want to switch to Trifluridine-tipiracil!!! I have told you this 3 times. I need to respond to...

I hear your frustration, and I'm sorry for not addressing this clearly before. Let me focus directly on what you need RIGHT NOW—questions to ask your oncologist about the switch to trifluridine-tipiracil.

Your Situation (Quick Context)

You have metastatic duodenal adenocarcinoma that has progressed despite two rounds of CAPOX (capecitabine + oxaliplatin). Your tumor has some important genetic features including an HRD signature and a BRCA1 mutation, which actually opens up specific treatment considerations. Your imaging shows active progression with new and growing lesions.

---

CRITICAL QUESTIONS TO ASK YOUR ONCOLOGIST ABOUT TRIFLURIDINE-TIPIRACIL:

1. Why trifluridine-tipiracil specifically for my case?

• "Given my BRCA1 mutation and HRD signature, why are you recommending trifluridine-tipiracil over other options like PARP inhibitors or platinum-based rechallenge?"
• (This matters because HRD-positive tumors often respond to specific targeted approaches)

2. Clinical trial eligibility—the key question you asked:

• "If I start trifluridine-tipiracil now, will that make me ineligible for clinical trials I might qualify for later?"
• "Are there any active clinical trials for duodenal cancer with my genetic profile that I should know about BEFORE starting this treatment?"
• (This is important because some trials have specific prior-treatment restrictions)

3. Expected outcomes with this drug:

• "What response rate do you expect with trifluridine-tipiracil for duodenal adenocarcinoma?"
• "How will we measure if it's working, and what's the timeline for reassessing?"
• "What would progression on this drug mean for next steps?"

4. Your specific genetic findings:

• "My tumor has an HRD signature and BRCA1 mutation—are there targeted therapies (like PARP inhibitors) that might be more effective than chemotherapy at this point?"
• "Why isn't a PARP inhibitor being considered given my HRD status?"

5. Side effects and quality of life:

• "What are the most common side effects, and how do they compare to CAPOX?"
• "Will this affect my ability to pursue other treatments if needed?"

6. Second opinion context (since you mentioned BC, Canada):

• "Would you support me getting a second opinion before starting this treatment?"
• "Can you provide my complete records (genomic test, imaging, pathology) for a second opinion consultation?"

---

About Trifluridine-Tipiracil (Educational Context)

What it is: Trifluridine-tipiracil (brand name Lonsurf) is a chemotherapy combination FDA-approved for metastatic colorectal cancer and gastric cancer. According to NCCN Guidelines, it's sometimes used in duodenal adenocarcinoma when other options have been exhausted, though duodenal cancer is less common.

Important note about YOUR case: Your genomic results show an HRD signature and BRCA1 mutation. According to ASCO Guidelines and NCCN recommendations, these findings typically make patients candidates for PARP inhibitors (like olaparib or rucaparib), which are often more effective than chemotherapy for HRD-positive tumors. This is a critical question to ask your oncologist.

---

Getting a Second Opinion in BC

Since you're in British Columbia and close to the US border:

1. BC Cancer Agency (provincial resource): Ask your oncologist for a referral to another BC Cancer specialist
2. Cross-border options: Some US cancer centers (Seattle, Portland) accept Canadian patients; check if your insurance covers this
3. Request your records: You have the right to your complete medical file—ask for:
   • FoundationOne CDx report
   • All imaging reports
   • Pathology report
   • Treatment history

---

Bottom Line for Your Response

Tell your oncologist: "Before I agree to start trifluridine-tipiracil, I need to understand: (1) Why this over PARP inhibitors given my HRD and BRCA1 status? (2) Will this affect my clinical trial eligibility? (3) Can I get a second opinion first?"

You have legitimate reasons to pause and ask these questions. Your genetic profile is actually quite informative, and your oncologist should be able to explain why trifluridine-tipiracil is the best choice for YOUR specific situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Guidelines for Gastric Cancer and Colorectal Cancer; ASCO Guidelines on HRD testing and PARP inhibitors; FDA approval information for trifluridine-tipiracil